| Eli Lilly And Company | 2.86M | US$3.29B | 8.6% |
| Merck & Company, Inc. | 16M | US$2.08B | 5.4% |
| Johnson & Johnson | 7.19M | US$1.84B | 4.8% |
| Astrazeneca Plc | 10.3M | US$1.75B | 4.6% |
| Unitedhealth Group Incorporated | 3.73M | US$1.55B | 4.0% |
| Gsk Plc | 44M | US$1.15B | 3.0% |
| Edwards Lifesciences Corporation | 11.4M | US$978M | 2.6% |
| Intuitive Surgical, Inc. | 2.73M | US$963M | 2.5% |
| Cvs Health Corporation | 9.21M | US$962M | 2.5% |
| Cencora, Inc. | 3.03M | US$945M | 2.5% |
| Vertex Pharmaceuticals Incorporated | 1.89M | US$902M | 2.4% |
| Abbvie Inc. | 3.51M | US$880M | 2.3% |
| Danaher Corporation | 4.28M | US$834M | 2.2% |
| Regeneron Pharmaceuticals, Inc. | 1.07M | US$818M | 2.1% |
| Novartis Ag | 4.66M | US$729M | 1.9% |
| Elevance Health, Inc. | 1.86M | US$698M | 1.8% |
| Argenx Se | 694K | US$642M | 1.7% |
| Hca Healthcare, Inc. | 1.59M | US$642M | 1.7% |
| Ucb S.a. | 2.48M | US$637M | 1.7% |
| Boston Scientific Corporation | 12.5M | US$583M | 1.5% |
| Agilent Technologies, Inc. | 4.12M | US$570M | 1.5% |
| Biogen Inc. | 2.75M | US$557M | 1.5% |
| Galderma Group Ag | 2.41M | US$525M | 1.4% |
| Roche Holding Ltd | 1.03M | US$450M | 1.2% |
| Dexcom, Inc. | 5.38M | US$449M | 1.2% |
| Alnylam Pharmaceuticals, Inc. | 2.14M | US$439M | 1.2% |
| Cardinal Health, Inc. | 1.9M | US$438M | 1.1% |
| Abbott Laboratories | 3.72M | US$393M | 1.0% |
| Shionogi & Co., Ltd. | 21.4M | US$387M | 1.0% |
| Centene Corporation | 6.15M | US$383M | 1.0% |
| Amgen Inc. | 985K | US$379M | 0.99% |
| Otsuka Holdings Co., Ltd. | 5.42M | US$376M | 0.99% |
| Revolution Medicines, Inc. | 1.99M | US$373M | 0.98% |
| United Therapeutics Corporation | 719K | US$372M | 0.98% |
| Genmab A/s | 1.28M | US$368M | 0.96% |
| Daiichi Sankyo Company, Limited | 22.7M | US$366M | 0.96% |
| Medtronic Plc. | 4.23M | US$361M | 0.95% |
| Chugai Pharmaceutical Co., Ltd. | 8.26M | US$359M | 0.94% |
| Stryker Corporation | 1.09M | US$354M | 0.93% |
| Ionis Pharmaceuticals, Inc. | 6.21M | US$322M | 0.84% |
| Incyte Corporation | 2.39M | US$285M | 0.75% |
| Ascendis Pharma A/s | 1.1M | US$268M | 0.70% |
| Thermo Fisher Scientific Inc | 459K | US$264M | 0.69% |
| Madrigal Pharmaceuticals, Inc. | 563K | US$263M | 0.69% |
| Cytokinetics, Incorporated | 3.34M | US$258M | 0.68% |
| Bridgebio Pharma, Inc. | 3.16M | US$253M | 0.66% |
| Steris Plc (ireland) | 1.1M | US$251M | 0.66% |
| Qiagen N.v. | 6.05M | US$250M | 0.66% |
| Eisai Co., Ltd. | 7.34M | US$221M | 0.58% |
| Cg Oncology, Inc. | 2.86M | US$204M | 0.53% |
| Bristol-myers Squibb Company | 3.06M | US$200M | 0.52% |
| Kymera Therapeutics, Inc. | 1.8M | US$186M | 0.49% |
| Scholar Rock Holding Corporation | 3.86M | US$183M | 0.48% |
| Protagonist Therapeutics, Inc. | 1.24M | US$170M | 0.45% |
| Dianthus Therapeutics, Inc. | 1.5M | US$161M | 0.42% |
| Novo Nordisk A/s Class B | 3.32M | US$157M | 0.41% |
| Ptc Therapeutics, Inc. | 2.31M | US$157M | 0.41% |
| Option Care Health, Inc. | 6.75M | US$155M | 0.41% |
| Icon Plc | 934K | US$153M | 0.40% |
| Heartflow, Inc. | 5.8M | US$146M | 0.38% |
| Celldex Therapeutics, Inc. | 3.78M | US$144M | 0.38% |
| Encompass Health Corporation | 1.25M | US$139M | 0.36% |
| Moderna, Inc. | 2.35M | US$129M | 0.34% |
| Vaxcyte, Inc. | 2.34M | US$127M | 0.33% |
| M3, Inc. | 9.45M | US$106M | 0.28% |
| Inspire Medical Systems, Inc. | 2.09M | US$105M | 0.28% |
| Alignment Healthcare, Inc. | 6.93M | US$103M | 0.27% |
| Arcus Biosciences, Inc. | 3.45M | US$97.1M | 0.25% |
| Zenas Biopharma, Inc. | 2.94M | US$92.3M | 0.24% |
| Immunome, Inc. | 3.7M | US$84.3M | 0.22% |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A | 9.54M | US$72.5M | 0.19% |
| Dyne Therapeutics, Inc. | 2.81M | US$70.7M | 0.19% |
| Zai Lab Ltd. | 36.4M | US$66.4M | 0.17% |
| Genfleet Therapeutics (shanghai), Inc. Class H | 18.5M | US$65.3M | 0.17% |
| Stoke Therapeutics, Inc. | 2.26M | US$65.2M | 0.17% |
| Duality Biotherapeutics, Inc. | 2.77M | US$64.4M | 0.17% |
| Pharvaris N.v. | 1.17M | US$38M | 0.10% |
| Kailera Therapeutics, Inc. | 2.19M | US$37.1M | 0.10% |
| Shandong Weigao Group Medical Polymer Co. Ltd. Class H | 77.1M | US$33M | 0.09% |
| Aktis Oncology, Inc. | 1.46M | US$32.3M | 0.08% |
| Definium Therapeutics, Inc. | 741K | US$32.2M | 0.08% |
| Nuvalent, Inc. | 0 | US$0 | 0.00% |
| Xenon Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Avantor, Inc. | 0 | US$0 | 0.00% |
| Natera, Inc. | 0 | US$0 | 0.00% |
| Crinetics Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Mineralys Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Acadia Healthcare Company, Inc. | 0 | US$0 | 0.00% |
| Bio-techne Corp | 0 | US$0 | 0.00% |
| Newamsterdam Pharma Company N.v. | 0 | US$0 | 0.00% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |